Lunai Bioworks (LNAI) EPS (Weighted Average and Diluted) (2022 - 2026)
Lunai Bioworks (LNAI) recorded quarterly EPS (Weighted Average and Diluted) of -$0.1 in Q1 2026, down 25.0% quarter-over-quarter from -$0.08 in Q4 2025, and up 62.33% on a YoY basis from -$0.06 in Q1 2025.
Lunai Bioworks (LNAI) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Lunai Bioworks' EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at -$0.1 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 62.33% year-over-year to -$0.1; the TTM figure through Mar 2026 stood at $2.05 (up 163.86% YoY), while the FY2025 annual figure was -$1.08, down 18.68% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.1 for Q1 2026 at Lunai Bioworks, down from -$0.08 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.1 in Q2 2025 to a low of -$2.76 in Q3 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.3 across 5 years, with a median of -$0.14 in 2022.
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) sank 1871.43% in 2024, then jumped 1279.74% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.08 in 2022, then rose by 12.5% to -$0.07 in 2023, then tumbled by 542.86% to -$0.45 in 2024, then jumped by 82.22% to -$0.08 in 2025, then dropped by 25.0% to -$0.1 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.1 (Q1 2026), -$0.08 (Q4 2025), and $0.13 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | -0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.08 |
| Sep 30, 2025 | 0.13 |
| Jun 30, 2025 | 2.10 |
| Mar 31, 2025 | -0.27 |
| Dec 31, 2024 | -0.45 |
| Sep 30, 2024 | -2.76 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | -0.07 |
| Sep 30, 2023 | -0.14 |
| Jun 30, 2023 | -0.41 |
| Mar 31, 2023 | -0.08 |
| Dec 31, 2022 | -0.08 |
| Sep 30, 2022 | -0.14 |
| Jun 30, 2022 | -1.72 |